LIH is pleased to announce that it has teamed up with Ayasdi (Menlo Park, CA, USA), a company that provides advanced data analytics solutions to Fortune 500 companies.

Building on expertise and research at the Department of Oncology, LIH will benefit from Ayasdi’s training and software, which will enable new progress in the area of precision medicine. In cancer research, this area is allowing the generation of novel ways for accurately predicting patients’ responses to specific treatments.

Different teams at the Department of Oncology will pool efforts to discover new connections between multiple “-omics” data sets and clinical information to predict responses to therapeutic interventions in two clinically-oriented domains: lung and brain cancers. The involved research units are the NorLux Neuro-Oncology Laboratory (Dr Francisco Azuaje, project coordinator, and Dr Sabrina Fritah, leader of the glioblastoma cancer project), the Genomics and Proteomics Research Unit (Arnaud Muller and Tony Kaoma, bioinformaticians) and the Lung Cancer Program of Luxembourg’s Partnership for Personalised Medicine (PPM) initiative (Dr Yeoun Jin Kim, leader of the lung cancer project).

“We are proud to partner with Ayasdi, a company that is already helping some of the world's most prestigious research and business organisations to accomplish major breakthroughs through smart data analysis”, states Dr Francisco Azuaje, who coordinates this new cooperation.

About Ayasdi

Ayasdi is transforming how the world uses data to solve complex problems. Founded in 2008 after a decade of research at Stanford, DARPA, and NSF, Ayasdi is pioneering a new approach for enterprises to automatically discover and operationalise insights from their data. Ayasdi’s Insight Discovery platform uses Topological Data Analysis (TDA) combined with an ensemble of machine learning techniques to enable data scientists, domain experts, and business people to achieve value from their data without the need to write code, queries, or ask questions. Funded by Khosla Ventures, Institutional Venture Partners, GE Ventures, Citi Ventures, and FLOODGATE, Ayasdi’s customers include General Electric, Citigroup, Merck, Anadarko, U.S. Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), the University of California San Francisco (UCSF), and Mount Sinai Hospital.